Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 4/2015

01.12.2015 | Original Article

Child and adolescent Down syndrome-associated leukaemia: the Irish experience

verfasst von: C. O’Rafferty, J. Kelly, L. Storey, C. Ryan, A. O’Marcaigh, O. Smith

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Down syndrome (DS), the most common syndromic chromosomal abnormality is associated with a unique susceptibility to develop both acute myeloid (ML) and lymphoblastic leukaemia (ALL). These leukaemias differ from the non-DS-related types of leukaemia and are thought to be distinct biological entities.

Aims

To perform a retrospective review of our experience of treating DS-related leukaemia at Our Lady’s Children’s Hospital.

Methods

Data were extracted from a database established in 2000 to prospectively gather data on DS-associated leukaemias and their outcomes following polychemotherapy. Kaplan–Meier survival curves were constructed.

Results

Nineteen patients with DS-ML were treated and 19 with DS-ALL. Sixteen (84 %) patients with DS-ML are alive and in complete remission with a median follow-up of 7 years. All deaths in this cohort were due to treatment-related mortality (TRM). Of the DS-ALL patients, 12 (63 %) remain alive with a median follow-up of 3.6 years. TRM accounted for five of the six deaths. One death was due to leukaemic relapse.

Conclusion

High cure rates are seen in DS-ML using contemporary polychemotherapy protocols, however, there is significant TRM in this cohort. DS-ALL does not have the same high cure rate as non-DS-ALL (>90 %) and again this is mainly due to an excess of TRM.
Literatur
2.
Zurück zum Zitat Bruwier A, Chantrain CF (2012) Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr 171(9):1301–1307CrossRefPubMed Bruwier A, Chantrain CF (2012) Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr 171(9):1301–1307CrossRefPubMed
3.
Zurück zum Zitat Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355(9199):165–169CrossRefPubMed Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355(9199):165–169CrossRefPubMed
4.
Zurück zum Zitat Xavier AC, Ge Y, Taub J (2010) Unique clinical and biological features of leukemia in Down syndrome children. Expert Rev Hematol 3(2):175–186CrossRefPubMed Xavier AC, Ge Y, Taub J (2010) Unique clinical and biological features of leukemia in Down syndrome children. Expert Rev Hematol 3(2):175–186CrossRefPubMed
6.
Zurück zum Zitat Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW et al (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood 107(12):4606–4613CrossRefPubMed Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW et al (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood 107(12):4606–4613CrossRefPubMed
7.
Zurück zum Zitat Dordelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G et al (1998) Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 12(5):645–651CrossRefPubMed Dordelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G et al (1998) Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 12(5):645–651CrossRefPubMed
8.
Zurück zum Zitat Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al (2005) Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 106(13):4043–4049CrossRefPubMed Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al (2005) Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 106(13):4043–4049CrossRefPubMed
9.
Zurück zum Zitat Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS et al (2005) Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 44(1):21–28CrossRefPubMed Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS et al (2005) Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 44(1):21–28CrossRefPubMed
10.
Zurück zum Zitat Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE et al (2001) Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 85(4):321–325PubMedCentralCrossRefPubMed Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE et al (2001) Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 85(4):321–325PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM et al (2013) Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123(1):70–77CrossRefPubMed Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM et al (2013) Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123(1):70–77CrossRefPubMed
12.
Zurück zum Zitat Izraeli S, Vora A, Zwaan CM, Whitlock J (2013) How I treat ALL in Down’s syndrome: pathobiology and management. Blood 123(1):35–40CrossRefPubMed Izraeli S, Vora A, Zwaan CM, Whitlock J (2013) How I treat ALL in Down’s syndrome: pathobiology and management. Blood 123(1):35–40CrossRefPubMed
13.
Zurück zum Zitat Patrick K, Wade R, Goulden N, Rowntree C, Hough R, Moorman AV et al (2014) Outcome of Down Syndrome associated Acute Lymphoblastic Leukaemia treated on a contemporary protocol. Br J Haematol 165(4):552–555CrossRefPubMed Patrick K, Wade R, Goulden N, Rowntree C, Hough R, Moorman AV et al (2014) Outcome of Down Syndrome associated Acute Lymphoblastic Leukaemia treated on a contemporary protocol. Br J Haematol 165(4):552–555CrossRefPubMed
14.
Zurück zum Zitat Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M (2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19(8):1355–1360CrossRefPubMed Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M (2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19(8):1355–1360CrossRefPubMed
15.
Zurück zum Zitat Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM et al (2006) Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 132(5):576–583CrossRefPubMed Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM et al (2006) Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 132(5):576–583CrossRefPubMed
17.
Zurück zum Zitat Buitenkamp TD, Mathot RA, de Haas V, Pieters R, Zwaan CM (2010) Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 95(7):1106–1113PubMedCentralCrossRefPubMed Buitenkamp TD, Mathot RA, de Haas V, Pieters R, Zwaan CM (2010) Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 95(7):1106–1113PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y (1996) Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 87(8):3395–3403PubMed Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y (1996) Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 87(8):3395–3403PubMed
19.
Zurück zum Zitat Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL et al (2010) Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood 116(7):1045–1050PubMedCentralCrossRefPubMed Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL et al (2010) Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood 116(7):1045–1050PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J et al (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41(11):1243–1246PubMedCentralCrossRefPubMed Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J et al (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41(11):1243–1246PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG et al (2012) Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120(17):3510–3518PubMedCentralCrossRefPubMed Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG et al (2012) Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120(17):3510–3518PubMedCentralCrossRefPubMed
Metadaten
Titel
Child and adolescent Down syndrome-associated leukaemia: the Irish experience
verfasst von
C. O’Rafferty
J. Kelly
L. Storey
C. Ryan
A. O’Marcaigh
O. Smith
Publikationsdatum
01.12.2015
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 4/2015
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-014-1212-2

Weitere Artikel der Ausgabe 4/2015

Irish Journal of Medical Science (1971 -) 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.